Aurora Announces Exclusive Rights to Cannabis Inhaler
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Nov. 5, 2015) – Aurora Cannabis Inc. (“Aurora” or the “Company”) (CSE:ACB)(OTCQB:ACBFF)(FRANKFURT:21P)(WKN:A1C4WM) is pleased to announce that it has entered into a letter of intent (“LOI”) for exclusive distribution rights to Mystabis, a revolutionary inhaler that provides pressurized metered doses of cannabis.
The terms of the arrangement allow Aurora sole Canadian distribution of the device. The ability to administer metered doses is something that both patients and the medical community have been waiting for eagerly. Without the use of any form of heat or combustion, this pressurized inhaler (“pMDI”) delivers exact quantities of cannabinoids in a manner that provides rapid medicinal effects while preserving the entourage effects of the cannabinoids and terpenoids. Physicians will find the delivery mechanism to be very familiar and will appreciate the precision controlled per dose delivery of both the THC and CBD dominant formulations.
Terry Booth, CEO, commented, “We are very excited to have the opportunity to bring what we believe to be a game-changing medical device to Canadians. Aurora’s scientists and our American partner scientists have conducted extensive research into the validity of this device and are confident that Health Canada, healthcare practitioners and patients are likely to recognize this easy-to-use delivery system as being amongst the safest, most consistent, and most reliable methods of effectively administering medical cannabis.”
The proposed transaction is subject to the completion of satisfactory due diligence. The finalized terms will be released upon closing of the definitive agreement.
Operations Update:
The Company is also pleased to provide an update of the status of its application to amend the license allowing for the sale of medical marijuana. The Company’s Chief Brand Officer, Neil Belot, commented, “As the Marihuana for Medical Purposes Regulation (“MMPR”) continues to evolve, Licensed Producers are being held to increasingly stringent standards by Health Canada, and Aurora welcomes the added scrutiny from the inspectors from Health Canada’s Regions and Programs Bureau who have been visiting the facility over the past few weeks. Aurora has been in continual dialogue with Health Canada’s Office of Medical Cannabis and is confident that these extra steps in the sales licencing process are in the best interest of Aurora shareholders, patients and the Office of Medical Cannabis. Our goal has always been to raise the bar for the medical cannabis industry in Canada and we are thrilled to be setting the new standards. Moving forward, we believe all Licenced Producers will be held to the same standards during their annual license renewal process and patients across the country will have an improved experience overall.”
About Aurora Cannabis Inc.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora’s wholly-owned subsidiary, Australis Capital Inc., seeks to be an active participant in the U.S. Cannabis market.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
Certain information contained in this news release, including information respecting the Company, the LOI, anticipated sales license approval, production capacity, production yields and other aspects of its anticipated future operations may be deemed “forward-looking”. All statements in this news release, other than statements of historical fact, that address events or developments that Aurora expects to occur, are “forward-looking information”. These statements relate to future events and reflect Aurora’s current expectations or beliefs and are based on information currently available to Aurora. Such forward looking information are based on the Company’s current operations, estimates, forecasts and projections and other factors and events that are not within the control of Aurora and there is no assurance they will prove to be correct. Forward-looking information is not a guarantee of future performance and actual results and future events could differ materially from those discussed in the forward-looking information. All of the forward-looking information contained in this news release is qualified by these cautionary statements. Although Aurora believes that the forward-looking information contained in this news release is based on reasonable assumptions, readers cannot be assured that actual results will be consistent with such statements. Accordingly, readers are cautioned against placing undue reliance on forward-looking information. Aurora expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise, except in accordance with applicable securities laws.
The CSE, securities commission or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Brayden Sutton
Director of Business Development
(604) 219-7104
brayden@auroramj.com
www.auroramj.com
- Published in Aurora Cannabis
Mobi724 S.R.L., a Wholly Owned Subsidiary of MOBI724 Global Solutions Inc. (CSE:MOS), Signs a Commercial Agreement With Movistar to Provide its Coupon Solution to Movistar’s 17 M Subscribers
MONTREAL, QUEBEC–(Marketwired – Nov. 5, 2015) – Mobi724 Global Solutions Inc. (“Mobi724” or the “Company”) (CSE:MOS), a technology leader in the digital incentives, couponing and payment space, announces that its wholly owned Argentinian subsidiary, Mobi724 S.R.L., has signed a commercial agreement with Movistar to design, implement, integrate, manage and support MOBI724’s mobile coupons solution for Movistar’s Discount and Rewards program.
MOBI724’s innovative global mobile couponing solution will allow Movistar to create, manage and send mobile campaigns to their 17 million subscribers, who will be able to redeem the couponing benefits directly at any point of sale operated by a participating retailer enrolled by MOBI724.
Marcel Vienneau, CEO of the Company, stated: “We are thrilled to team up with such a global leader and offer the best of breed mobile couponing solution for Movistar’s benefits program, a major communication platform, for their 17 million customers. This level of confidence confirms that our approach in developing innovative value added solutions in a very competitive market is gaining momentum.”
About Movistar
Movistar is the major Spanish mobile phone operator owned by Telefónica S.A. It operates in Spain and in most Latin American countries (including Argentina, Brazil, Chile, Uruguay, Peru, Ecuador, Venezuela, Colombia, Mexico, Guatemala, Panamá, El Salvador, Costa Rica and Nicaragua). Movistar is the largest carrier in Spain with 22 million customers (cellphone services only) and 41.58{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of market share. In Latin America, Movistar has a 30{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} market share with almost 200 million subscribers. In Argentina, Movistar has a 35{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} market share with a base of 17 million subscribers.
About Mobi724 Global Solutions
Mobi724 Global Solutions (CSE:MOS), a corporation based in Montreal, Canada, is a technology leader in digital incentives and payment solutions. It offers a unique and fully integrated suite of solutions – PAYMENT-COUPONING AND LOYALTY all in one.
Our vision is to enhance the value of commoditized payment transactions to the players in this eco-system (ex: customers, banks, mobile carriers and retailers) by adding layers of intelligence to these transactions (i.e. smart transactions) in a seamless manner.
Mobi724 Global Solutions unleashes the true potential of both payment and couponing/rewards transactions for both online and offline points of sale.
The Corporation is fully dedicated to delivering unique “real time” and seamless digital promotional incentives (coupons including card linked coupons, bank cards, loyalty rewards) embedded into the most secured payment environment. The Corporation provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enable retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to ANY mobile device and allow its redemption at ANY point of sales.
Their credit and debit EMV payment solutions will allow banks to process end to end EMV transactions, focusing on authentication, approved security and quick merchant adoption which allows the users to process payments with a wide range of devices over a secure and seamless transaction.
Mobi724’s PCI and EMV cloud-based switch, with their device agnostic connectivity, simplifies deployment and integration, and introduces new payment and digital incentives solutions to the market enabling multi layered intelligent transactions therefore SMART TRANSACTIONS.
For more information on its products and on Mobi724 Global Solutions, visit www.mobi724globalsolutions.com.
Certain statements in this document, including those which express management’s expectations or estimations with regard to the Company’s future performance, constitute “forward-looking statements” as understood by applicable securities laws. Forward-looking statements are, of necessity, based on a certain number of estimates and hypotheses; while management considers these to be accurate at the time they are expressed, they are inherently subject to significant uncertainties and risks on the commercial, economic and competitive levels. We advise readers that these forward-looking statements are subject to risks, uncertainties, and other known and unknown factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Investors are advised to not rely unduly on the forward-looking statements. This advisory applies to all forward-looking statements, whether expressed orally or in writing, attributed to the Company or to any individual expressing them in the name of the Company. Unless required by law, the Company is under no obligation to publicly update these forward-looking statements, whether to reflect new information, future events, or other circumstances.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. This news release does not constitute a solicitation to buy or sell any securities in the United States.
Mr. Marcel Vienneau
1-514-394-5200 Ext 413
www.mobi724globalsolutions.com
- Published in Mobi724 Global Solutions
OrganiGram Secures $6,350,000 in a Non-Brokered Private Placement to Position the Company for National Legalization
MONCTON, NEW BRUNSWICK–(Marketwired – Nov. 5, 2015) – OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQX:OGRMF) (“OrganiGram” or the “Company“) is pleased to announce that, subject to TSX Venture Exchange approval, the Company has secured a non-brokered private placement offering for net proceeds of $6,350,000 (the “Offering”).
The Company will issue an aggregate of 3,298,077 units (“Units”) at a price of $1.04 per Unit (the “Offering Price”) for net proceeds of $3,430,000. Each Unit consists of one common share of the Company (a “Common Share”), and one-half of a share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable into one additional Common Share (a “Warrant Share”) of the Company at $1.40 per Warrant Share for a period of eighteen (18) months from closing of the Offering. The Company intends to use the proceeds from the Offering for accelerated facility expansion and general working capital purposes.
In addition, the Company has secured convertible debentures in the aggregate amount of $2,920,000 which carry an interest rate of 6.75{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and which mature on December 31, 2018. The debentures may be converted by the debenture holder at a ratio of 714.286 shares per $1,000 of the principal amount converted.
“OrganiGram is pleased to have secured this financing. Management appreciates the confidence demonstrated by its Board of Directors, as all members of the Board participated in this financing round. With the newly elected Federal Government’s platform position to legalize recreational marijuana, the Company looks forward to allocating this capital effectively to expand the facility, enhance working capital and continue marketing initiatives.” said Roger Rogers, President & CFO.
It is anticipated that related parties of the Company will acquire shares and warrants under the private placement. Such participation would be considered to be “related party transactions” within the meaning of the TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 (“MI 61-101”). The company intends to rely on the exemptions from the formal valuation and minority approval requirements of MI 61-101 in respect of related party participation as at the time the transaction is agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves interested parties, exceeds 25 per cent of the Company’s market capitalization.
Completion of this placement is subject to the approval of the TSX Venture Exchange.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
On behalf of the board of directors,
Denis Arsenault
Director and CEO
OrganiGram Holdings Inc.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of operations — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Brett Allan
Director of Investor Relations
OrganiGram Holdings Inc.
(647) 229-6627
www.organigram.ca
- Published in Organigram Holdings
InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Nov. 4, 2015) – InMed Pharmaceuticals Inc. (“InMed”) (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
InMed is now pleased to report that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation. InMed has been studying the potential of certain cannabinoids to expedite the wound healing process using the electric cell-substrate impedance sensing (ECIS) wounding assay. The ECIS wounding assay is a state-of-the-art assay that replaces the traditional scrape or scratch assay. Using this assay, InMed has been able to identify certain cannabinoids that significantly potentiate the wound healing process, when compared to other less active cannabinoids, or to the vehicle control. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “The results we are obtaining with the ECIS wound assay are significant for the development of INM-750. Through the use of the ECIS assay we are able to demonstrate the wound healing and skin regeneration properties of INM-750; these properties will be critical to help alleviate the primary symptoms of patients with EB”.
In addition to the ECIS studies, InMed has also studied the anti-inflammatory effect of certain cannabinoids included in INM-750. It has been demonstrated that cannabinoids included in INM-750 are able to down regulate the production of IL-8 by human keratinocytes, and inhibit IFNɣ/TNF⍺ induced production of IL-6 by human keratinocytes. Dr. Sazzad states, “These results are important to demonstrate that in addition to having an effect on wound healing, the cannabinoids included in INM-750 should also help down regulate the chronic inflammation that is present in EB patients”.
InMed continues to develop INM-750 with the goal of entering the clinic in the first half of 2016. Initial proof of concept studies in human subjects should be completed by the end of 2016. Paul Brennan, CEO of InMed says “I am pleased with the progress of our development program, and the data that has been generated by Dr. Hossain and his colleagues. INM-750 has the potential to provide a significant addition to the treatment options for patients with EB and EBS.”
A summary of the pre-clinical results on INM-750 is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in friction and skin fragility. The severity of this condition ranges from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Investors
Paul Brennan
President and Chief Executive Officer
604.669.7207
paul@inmedpharma.com
Chris Bogart
SVP, Corporate Strategy and Investor Relations
604.669.7207
chris@inmedpharma.com
- Published in News Home
Mobi724 (MOS:CSE) Signs a Commercial Agreement With Movistar
MOBI724 Global Solutions Inc. (MOS:CSE), Signs a Commercial Agreement With Movistar to Provide its Coupon Solution to Movistar’s 17 M Subscribers
Mobi724 Global Solutions Inc. (“Mobi724” or the “Company”) (MOS:CSE), a technology leader in the digital incentives, couponing and payment space, announces that its wholly owned Argentinian subsidiary, Mobi724 S.R.L., has signed a commercial agreement with Movistar to design, implement, integrate, manage and support MOBI724’s mobile coupons solution for Movistar’s Discount and Rewards program.
MOBI724’s innovative global mobile couponing solution will allow Movistar to create, manage and send mobile campaigns to their 17 million subscribers, who will be able to redeem the couponing benefits directly at any point of sale operated by a participating retailer enrolled by MOBI724.
Marcel Vienneau, CEO of the Company, stated: “We are thrilled to team up with such a global leader and offer the best of breed mobile couponing solution for Movistar’s benefits program, a major communication platform, for their 17 million customers. This level of confidence confirms that our approach in developing innovative value added solutions in a very competitive market is gaining momentum.”
About Movistar
Movistar is the major Spanish mobile phone operator owned by Telefónica S.A. It operates in Spain and in most Latin American countries (including Argentina, Brazil, Chile, Uruguay, Peru, Ecuador, Venezuela, Colombia, Mexico, Guatemala, Panamá, El Salvador, Costa Rica and Nicaragua). Movistar is the largest carrier in Spain with 22 million customers (cellphone services only) and 41.58{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of market share. In Latin America, Movistar has a 30{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} market share with almost 200 million subscribers. In Argentina, Movistar has a 35{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} market share with a base of 17 million subscribers.
About Mobi724 Global Solutions
Mobi724 Global Solutions (CSE:MOS), a corporation based in Montreal, Canada, is a technology leader in digital incentives and payment solutions. It offers a unique and fully integrated suite of solutions – PAYMENT-COUPONING AND LOYALTY all in one.
Our vision is to enhance the value of commoditized payment transactions to the players in this eco-system (ex: customers, banks, mobile carriers and retailers) by adding layers of intelligence to these transactions (i.e. smart transactions) in a seamless manner.
Mobi724 Global Solutions unleashes the true potential of both payment and couponing/rewards transactions for both online and offline points of sale.
The Corporation is fully dedicated to delivering unique “real time” and seamless digital promotional incentives (coupons including card linked coupons, bank cards, loyalty rewards) embedded into the most secured payment environment. The Corporation provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enable retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to ANY mobile device and allow its redemption at ANY point of sales.
Their credit and debit EMV payment solutions will allow banks to process end to end EMV transactions, focusing on authentication, approved security and quick merchant adoption which allows the users to process payments with a wide range of devices over a secure and seamless transaction.
Mobi724’s PCI and EMV cloud-based switch, with their device agnostic connectivity, simplifies deployment and integration, and introduces new payment and digital incentives solutions to the market enabling multi layered intelligent transactions therefore SMART TRANSACTIONS.
For more information on its products and on Mobi724 Global Solutions, visit www.mobi724globalsolutions.com.
InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa
Vancouver, BC – November 04, 2015 – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
InMed is now pleased to report that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation. InMed has been studying the potential of certain cannabinoids to expedite the wound healing process using the electric cell-substrate impedance sensing (ECIS) wounding assay. The ECIS wounding assay is a state-of-the-art assay that replaces the traditional scrape or scratch assay. Using this assay, InMed has been able to identify certain cannabinoids that significantly potentiate the wound healing process, when compared to other less active cannabinoids, or to the vehicle control. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “The results we are obtaining with the ECIS wound assay are significant for the development of INM-750. Through the use of the ECIS assay we are able to demonstrate the wound healing and skin regeneration properties of INM-750; these properties will be critical to help alleviate the primary symptoms of patients with EB”.
In addition to the ECIS studies, InMed has also studied the anti-inflammatory effect of certain cannabinoids included in INM-750. It has been demonstrated that cannabinoids included in INM-750 are able to down regulate the production of IL-8 by human keratinocytes, and inhibit IFNɣ/TNF⍺ induced production of IL-6 by human keratinocytes. Dr. Sazzad states, “These results are important to demonstrate that in addition to having an effect on wound healing, the cannabinoids included in INM-750 should also help down regulate the chronic inflammation that is present in EB patients”.
InMed continues to develop INM-750 with the goal of entering the clinic in the first half of 2016. Initial proof of concept studies in human subjects should be completed by the end of 2016. Paul Brennan, CEO of InMed says “I am pleased with the progress of our development program, and the data that has been generated by Dr. Hossain and his colleagues. INM-750 has the potential to provide a significant addition to the treatment options for patients with EB and EBS.”
A summary of the pre-clinical results on INM-750 is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in friction and skin fragility. The severity of this condition ranges from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
CONTACT: Investors
Paul Brennan
President and Chief Executive Officer
Tel: 604.669.7207
Email: paul@inmedpharma.com
or
Chris Bogart
SVP, Corporate Strategy and Investor Relations
Tel: 604.669.7207
Email: chris@inmedpharma.com
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals
InMed’s (IN:CSE) INM-750 Shows Positive Effects on Wound Healing
InMed Provides Update on Progress of Its Development Program for Epidermolysis Bullosa
Including New Pre-clinical Results on the Wound Healing and Anti-inflammatory Properties of INM-750
InMed Pharmaceuticals Inc. (“InMed”) (IN:CSE)(IMLFF:OTCQB), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies would like to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
InMed is now pleased to report that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation. InMed has been studying the potential of certain cannabinoids to expedite the wound healing process using the electric cell-substrate impedance sensing (ECIS) wounding assay. The ECIS wounding assay is a state-of-the-art assay that replaces the traditional scrape or scratch assay. Using this assay, InMed has been able to identify certain cannabinoids that significantly potentiate the wound healing process, when compared to other less active cannabinoids, or to the vehicle control. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, “The results we are obtaining with the ECIS wound assay are significant for the development of INM-750. Through the use of the ECIS assay we are able to demonstrate the wound healing and skin regeneration properties of INM-750; these properties will be critical to help alleviate the primary symptoms of patients with EB”.
In addition to the ECIS studies, InMed has also studied the anti-inflammatory effect of certain cannabinoids included in INM-750. It has been demonstrated that cannabinoids included in INM-750 are able to down regulate the production of IL-8 by human keratinocytes, and inhibit IFN╔ú/TNFΓì║ induced production of IL-6 by human keratinocytes. Dr. Sazzad states, “These results are important to demonstrate that in addition to having an effect on wound healing, the cannabinoids included in INM-750 should also help down regulate the chronic inflammation that is present in EB patients”.
InMed continues to develop INM-750 with the goal of entering the clinic in the first half of 2016. Initial proof of concept studies in human subjects should be completed by the end of 2016. Paul Brennan, CEO of InMed says “I am pleased with the progress of our development program, and the data that has been generated by Dr. Hossain and his colleagues. INM-750 has the potential to provide a significant addition to the treatment options for patients with EB and EBS.”
A summary of the pre-clinical results on INM-750 is available on InMed’s website under the Investors and the Pipeline sections.
About Epidermolysis bullosa simplex (EBS)
Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in friction and skin fragility. The severity of this condition ranges from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available.
About InMed
InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Medical Marijuana
Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
VANCOUVER, BC–(Marketwired – November 03, 2015) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the “Company“) is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason’s role will be primarily to provide strategic advice and an action plan for the Company’s glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.
Mason has extensive experience in the pharmaceutical and biotech fields. He has held various medical and commercial responsibilities at Amgen, including leading the commercialization of their new products, and at GlaxoSmithKline leading medical affairs for their specialty care portfolio. Most recently, Mason was the Vice President of Medical Affairs at Nordion, where he focused on the development and commercialization of TheraSphere®, which was sold to BTG for $200 million.
Mason earned his Honors Bachelor of Science in Physiology (1997), Doctor of Medicine (2001) and Master of Business Administration (2010) from the University of Western Ontario.
“I look forward to working closely with management on the glycoprotein project over the next few months,” said Dr. Mason Ross. “I can’t think of a company that is better positioned than Sirona to demonstrate how novel carbohydrate technology may result in a wide range of useful products. The potential for this technology may be enormous.”
“We decided to bring Mason on board for his proven biotech/pharma successes and to support us in building a plan to commercialize our glycoproteins while we direct our immediate efforts towards closing a major transaction for our newest skin-lightener,” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in News Home
Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
Vancouver, British Columbia – November 3, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB), (the “Company”) is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason’s role will be primarily to provide strategic advice and an action plan for the Company’s glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.
Mason has extensive experience in the pharmaceutical and biotech fields. He has held various medical and commercial responsibilities at Amgen, including leading the commercialization of their new products, and at GlaxoSmithKline leading medical affairs for their specialty care portfolio. Most recently, Mason was the Vice President of Medical Affairs at Nordion, where he focused on the development and commercialization of TheraSphere®, which was sold to BTG for $200 million.
Mason earned his Honors Bachelor of Science in Physiology (1997), Doctor of Medicine (2001) and Master of Business Administration (2010) from the University of Western Ontario.
“I look forward to working closely with management on the glycoprotein project over the next few months,” said Dr. Mason Ross. “I can’t think of a company that is better positioned than Sirona to demonstrate how novel carbohydrate technology may result in a wide range of useful products. The potential for this technology may be enormous.”
“We decided to bring Mason on board for his proven biotech/pharma successes and to support us in building a plan to commercialize our glycoproteins while we direct our immediate efforts towards closing a major transaction for our newest skin-lightener,” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000
Vancouver, BC — November 2, 2015 – InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), is pleased to announce that it will conduct a non-brokered private placement of up to 6,666,667 units (“Units”) at a price of $0.15 per Unit for aggregate gross proceeds of up to C$1,000,000. Each Unit will consist of one common share and one of one non-transferable share purchase warrant. Each whole warrant will be exercisable by the holder to acquire one additional common share at a price of $0.30 for a period of twelve (12) months following the closing of the financing.
Completion of the private placement is subject to receipt of regulatory approval. All securities issued will be subject to a statutory four month hold period under applicable Securities Laws.
The net proceeds from this private placement will be used for general working capital purposes. Finders’ fees in cash or warrants may be payable in accordance with the policies of the Exchange.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
Paul Brennan
President and Chief Executive Officer
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals